{"atc_code":"S01","metadata":{"last_updated":"2020-09-06T07:15:23.817503Z","applied_components":{"decision_date_extraction":{"output_fields":["attachment.decision_date"],"input_checksum":"ea1481e4135e3cf4c3ea6fa8b197b9b2d01cea08ba01858c9eb66a7477454c03","last_success":"2021-01-21T17:06:13.663325Z","output_checksum":"f429f64808d84b4b08098bf403595a8de2439affb9624c54bcfd025793addffd","success":true,"name":"decision_date_extraction","input_fields":["attachment.type","attachment.content"],"version":1,"finish_time":"2021-01-21T17:06:13.663325Z","status":"NOT_APPLICABLE"},"study-ids-enricher":{"output_fields":["attachment.studies","attachment.max_study_phase"],"input_checksum":"30552476228703649e234e2755ed38d4ab04c17ab7f17fac54ed7f50f93bdece","last_success":"2021-01-21T17:01:16.383093Z","output_checksum":"f429f64808d84b4b08098bf403595a8de2439affb9624c54bcfd025793addffd","success":true,"name":"study-ids-enricher","input_fields":["attachment.type","active_substance","attachment.content"],"version":27,"finish_time":"2021-01-21T17:01:16.383093Z","status":"NOT_APPLICABLE"},"EmaDataAccessor":{"output_fields":[],"input_checksum":"44136fa355b3678a1146ad16f7e8649e94fb4fc21fe77e8310c060f61caaff8a","last_success":"2020-09-06T07:15:23.817498Z","output_checksum":"44136fa355b3678a1146ad16f7e8649e94fb4fc21fe77e8310c060f61caaff8a","success":true,"name":"EmaDataAccessor","input_fields":[],"version":3,"finish_time":"2020-09-06T07:15:23.817498Z","status":"UP_TO_DATE"},"historic_pivotal_studies":{"output_fields":["attachment.studies.known_pivotal"],"input_checksum":"f429f64808d84b4b08098bf403595a8de2439affb9624c54bcfd025793addffd","last_success":"2020-09-10T12:26:12.121362Z","output_checksum":"f429f64808d84b4b08098bf403595a8de2439affb9624c54bcfd025793addffd","success":true,"name":"historic_pivotal_studies","input_fields":["attachment.studies.study_ids"],"version":2,"finish_time":"2020-09-10T12:26:12.121362Z","status":"UP_TO_DATE"},"section_ranges_extraction":{"output_fields":["attachment.labelSections"],"input_checksum":"ea1481e4135e3cf4c3ea6fa8b197b9b2d01cea08ba01858c9eb66a7477454c03","last_success":"2020-12-07T17:22:30.832215Z","output_checksum":"f429f64808d84b4b08098bf403595a8de2439affb9624c54bcfd025793addffd","success":true,"name":"section_ranges_extraction","input_fields":["attachment.type","attachment.content"],"version":2,"finish_time":"2020-12-07T17:22:30.832215Z","status":"UP_TO_DATE"},"AttachmentDownloader":{"output_fields":["attachment.content","attachment.first_published","attachment.last_updated"],"input_checksum":"8f13dca0597086e9757140882f080d21a9838e8b88f109756daf3e929210ec00","last_success":"2020-12-03T22:27:22.932045Z","output_checksum":"9a0c56b6b204536de2ab857e9a693f6618a31022dbcfc1f44fd6c8b64c5b6de1","success":true,"name":"AttachmentDownloader","input_fields":["attachment.link"],"version":2,"finish_time":"2020-12-03T22:27:22.932045Z","status":"UP_TO_DATE"},"prime_designation_enricher":{"output_fields":["prime_designation"],"input_checksum":"ea1481e4135e3cf4c3ea6fa8b197b9b2d01cea08ba01858c9eb66a7477454c03","last_success":"2020-12-07T17:06:55.475847Z","output_checksum":"dcf4d2ed94fa29974e643bd4a70cd26ec785f1130958f3e23e8022193699a97a","success":true,"name":"prime_designation_enricher","input_fields":["attachment.type","attachment.content"],"version":3,"finish_time":"2020-12-07T17:06:55.475847Z","status":"UP_TO_DATE"},"rapporteur_extraction":{"output_fields":["attachment.co_rapporteur","attachment.main_rapporteur"],"input_checksum":"ea1481e4135e3cf4c3ea6fa8b197b9b2d01cea08ba01858c9eb66a7477454c03","last_success":"2021-01-21T17:14:01.086420Z","output_checksum":"f429f64808d84b4b08098bf403595a8de2439affb9624c54bcfd025793addffd","success":true,"name":"rapporteur_extraction","input_fields":["attachment.type","attachment.content"],"version":2,"finish_time":"2021-01-21T17:14:01.086420Z","status":"NOT_APPLICABLE"}},"agency":"EMA","product_id":"FD9043BC3619FD52CC0AAC3FF3DAB81E","direct_link":"https://www.ema.europa.eu/en/medicines/human/EPAR/omidria","first_created":"2020-09-06T07:15:23.812085Z","component_failures":{"section_ranges_extraction":"com.bayer.rapid.rest.RestEnricherException: Enricher returned error code 500, message: Internal Server Error","AttachmentDownloader":"java.lang.RuntimeException: java.lang.RuntimeException: org.apache.tika.exception.TikaException: TIKA-198: Illegal IOException from org.apache.tika.parser.pdf.PDFParser@d42a600","prime_designation_enricher":"com.bayer.rapid.rest.RestEnricherException: Enricher returned error code 500, message: Internal Server Error"}},"revision_number":6,"approval_status":"authorised","active_substance":["ketorolac","phenylephrine"],"additional_monitoring":false,"inn":"phenylephrine / ketorolac","prime_designation":false,"accelerated_assessment":false,"orphan":false,"product_name":"Omidria","authorization_holder":"Omeros Ireland Limited","generic":false,"product_number":"EMEA/H/C/003702","initial_approval_date":"2015-07-28","attachment":[{"last_updated":"2020-08-13","oldtype":"product-information","link":"https://www.ema.europa.eu/documents/product-information/omidria-epar-product-information_en.pdf","id":"6DE5DD3ADB6522D4F53BA079E4566103","type":"productinformation","title":"Omidria : EPAR - Product Information","first_published":"2015-09-01","content":"Skip to main content\n\n\n\n\n\n    \n    \n  \n\n\n    \n      \n\n      \n\n      \n\n    \n\n      \n\n\n\n  \n    \n      \n        \n      \n      Menu\n    \n          \t\n                                    \n                            \n\n\n      \n\n\n\n\n\n  \n\n\n\n  \n  \n    \n      \n        \n                              \n\n    \n\n  \n\n\n  \n    \n      \n        \n                  \n            EMA website temporarily unavailable\n\nThis website is currently unavailable due to essential maintenance.\n\nEmergency contact details\n\nTo report a potentially serious problem with a centrally authorised medicine, call our product emergency hotline on +31 (0)88 781 7600.\n\nTo report a product quality defect, including a suspected defect, of a centrally authorised medicine that could result in a recall or abnormal restriction on supply, marketing or manufacturing authorisation holders can call +31 (0)65 008 9457 outside business hours.\n\nThe details of your call may be documented, including personal data if you provide them (such as your name, contact details and nature of the issue raised), in accordance with our privacy statement. You can consult our privacy statement at https://www.ema.europa.eu/en/about-us/legal/general-privacy-statement once the website is back online.\n          \n\n              \n    \n\n  \n\n\n\n\n  \n  \n  \n      \n          \n        RSS feed\n      Twitter\n      YouTube\n      LinkedIn\n    \n\n      \n\n\n  \n    \n      Â© 1995-2020 European Medicines Agency    \n\n    \n      European Union agencies network\n      \n        \n\n      \n\n    \n\n    \n      An agency of the European Union","content_length":1552,"file_size":34283}],"conditional_approval":false,"exceptional_circumstances":false,"indication":"<div> \n <div class=\"ecl-field__body\"> \n  <div class=\"ecl-editor first last\">\n   <p>Omidria is indicated in adults for maintenance of intraoperative mydriasis, prevention of intraoperative miosis and reduction of acute postoperative ocular pain in intraocular lens replacement surgery.</p>\n  </div> \n </div> \n</div>","therapeutic_area":["Lens Implantation, Intraocular","Pain, Postoperative"],"contact_address":"Omeros Ireland Limited\nOrmond Building\n31-36 Ormond Quay Upper\nDublin 7\nIreland","biosimilar":false}